Increasing Operational Capacity and Reducing Costs of Rituximab Administration: A Costing Analysis

Abstract

Using TDABC, we demonstrate that rituximab cost is the primary driver of treatment cost, but capacity is largely driven by treatment time. Subcutaneous rituximab leads to higher capacity than biosimilar rituximab across a range of plausible costs; its use in rheumatology should be studied.